An analysis published in Health Affairs Scholar examined FDA advisory committee meetings over a recent 20-year period and found that nearly 40% included a patient or consumer representative with active ties to an advocacy group funded by pharmaceutical companies. On several committees, that share exceeded 50%. The authors also found that more than one in ten meetings included a representative affiliated with an organization that received funding from the drugmaker whose medicine was being reviewed.
The analysis highlights a gap in FDA conflict-of-interest policy. While the agency has well-established rules for scientific advisory committee members, policies for patient and consumer representatives are less developed, especially regarding industry funding of advocacy groups. Most of the organizational ties were not disclosed at the meetings, raising questions about potential undue industry influence on voting behavior.
The authors say the findings point to a need for clearer disclosure requirements and conflict-of-interest standards for patient and consumer representatives. The study does not allege that these ties influenced any specific vote, but it underscores a structural vulnerability in how the FDA seeks patient input during drug reviews.